Structure via PubChem · Public domain (PubChem)
zibotentan
Sign in to saveAlso known as ZD 4054, ZD-4054, ZD4054
Zibotentan (INN; development code ZD4054) is an experimental anti-cancer drug candidate in development by AstraZeneca. It is an endothelin receptor antagonist.
Chemical data
- Formula
- C19H16N6O4S
- Molecular weight
- 424.4 g/mol
- IUPAC name
- N-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide
- SMILES
- CC1=CN=C(C(=N1)OC)NS(=O)(=O)C2=C(N=CC=C2)C3=CC=C(C=C3)C4=NN=CO4
- InChIKey
- FJHHZXWJVIEFGJ-UHFFFAOYSA-N
- XLogP
- 1.4
- Polar surface area
- 141 Ų
- H-bond donors
- 1
- H-bond acceptors
- 10
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Phase 3
- Molecule type
- Small molecule
- Indications
- liver disease, prostate adenocarcinoma, non-small cell lung carcinoma, intermittent vascular claudication
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 424.095374
Show 2 more facts
- chemical formula
- C₁₉H₁₆N₆O₄S
- canonical SMILES
- CC1=CN=C(C(=N1)OC)NS(=O)(=O)C2=C(N=CC=C2)C3=CC=C(C=C3)C4=NN=CO4
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- References
- External links
Zibotentan (INN; development code ZD4054) is an experimental anti-cancer drug candidate in development by AstraZeneca. It is an endothelin receptor antagonist.
Zibotentan was granted fast track status for the treatment of prostate cancer by the FDA.
Excerpted from Wikipedia’s “zibotentan” article, available under the CC BY-SA 4.0 licence.
Available in 8 languages
via Wikidata sitelinks · CC0